CSI Market
Sign In | Register

Rvl Pharmaceuticals Plc (RVLP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RVLP quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Rvl Pharmaceuticals Plc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2017)
Operating Activities
Income-103.38
Depreciation & amortization0.38
Amortization of Other Assets3.06
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.05
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.88
Share-based Compensation4.07
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-1.27
Impairment Of Intangible Assets Excluding Goodwill13.31
Payment For Contingent Consideration Liability Operating Activities-
Impairment Of Fixed And Intangible Assets Excluding Goodwill-
Non Cash Interest And Amortization Of Debt Issuance Costs And Discounts-
Change In Fair Value Of Debt-10.00
Increase Decrease In Accrued And Other Current Liabilities2.32
Income taxes-0.09
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.90
Increase (Decrease) in Accounts Payable, Trade-1.37
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets4.28
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities52.61
Discontinued operations0.00
Net Cash flow from Operating Activities-37.81
Investing Activities
Capital Expenditures-0.75
Sale of Capital Items0.88
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments On Disposal Of Leased Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.13
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings19.09
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock23.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.15
Proceeds From Insurance Financing Loan1.72
Repayment Of Insurance Financing Loan-2.70
Finance Lease Principal Payments-
Proceeds From Purchases Of Stock Under Employee Stock Purchase Plan0.19
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities41.78
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-37.68
Total Cash Flow4.10
4 historic quarters locked

Sign in to unlock the full Rvl Pharmaceuticals Plc cash flow history.

Sign In Create Free Account

About Rvl Pharmaceuticals Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-014733

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License